Objective: To determine whether microRNA (miRNA) profiling of primary lung and head and neck squamous cell carcinomas could be useful to identify a specific miRNA signature that can be used to further discriminate between primary lung squamous carcinomas and metastatic lesions in patients with a history of head and neck squamous cell cancer.
Perspective
The distinction between a primary lung squamous cell carcinoma and a metastatic lesion in a patient with a history of head and neck squamous cancer is challenging but essential to determine the proper treatment. MicroRNA profiling can help discriminate tumors from different tissues of origin. MiR-34a and miR10a:10b may be especially useful in differentiating between a primary and a metastatic lesion.
See Editorial Commentary page 728.
Differentiating between a primary lung squamous cell carcinoma (LSCC) and a metastatic lesion in a patient with a history of head and neck squamous cell carcinoma (HNSCC) is challenging with the use of standard histopathology techniques. Both LSCC and HNSCC have several features in common, including similar histology, epithelial cells of origin, and association with tobacco exposure. 1, 2 Even though the rate of metastasis from HNSCC is relatively low and may depend on locoregional control and lymph node status, the lungs frequently are involved, accounting for up to 70% to 85% of HNSCC metastatic cases. 3 Patients with a history of HNSCC who present with new lung lesions can therefore represent a challenge for surgeons who must plan the appropriate therapeutic approach. In patients with locoregional control of their HNSCC with metastasis to the lung, a complete, nonanatomical or wedge resection is indicated. However, the standard of care for primary LSCC is an anatomical resection, which includes a segmentectomy, lobectomy, or pneumonectomy, which have greater morbidity and perioperative mortality compared with nonanatomic resections. 4 MicroRNAs (miRNAs) regulate gene expression and are involved in multiple biologic processes, including cell differentiation, proliferation, apoptosis, and metastasis. 5 Their role in the development and pathogenesis of cancer also has been described, 6 and it is known that miRNAs can act as tumor suppressors and oncogenes. 5 It also has been shown that miRNAs can be expressed differentially between different tissues and tumor types, and their expression can differentiate tumors with different developmental origin. 7 MiRNA profiling is a well-accepted method for the identification of specific miRNAs related to different diseases and types of cancer. 5, 8 This could be useful in the diagnosis of metastatic cancer of unknown primary site 8 and in tumors with similar histopathologic findings in which a diagnosis under light microscopy can be challenging.
An accurate diagnosis of a new lung lesion in a patient with history of HNSCC is essential because this will help determine the appropriate therapeutic approach and surgical resection extent. In this study, we aimed to determine whether miRNA profiling is useful to differentiate between primary LSCC and HNSCC to identify characteristic features that are useful for differentiating between a primary LSCC and a metastatic lesion in a patient with history of HNSCC. LSCC and 17 HNSCC specimens from patients without a previous history of cancer or chemo/radiotherapy were selected for analysis. LSCC tissue was resected via segmentectomy, lobectomy, and pneumonectomy. Two patients with poor pulmonary function were not good candidates for anatomical resections and underwent wedge resection of their lung nodules. HNSCC were taken from the larynx, oropharynx, oral cavity, and floor of the mouth. Human papillomavirus (HPV) status was assessed by P16 staining in all HNSCC cases. The FFPE samples were sectioned with a microtome into four 10-mm sections and placed in a capped 1.5-mL centrifuge tube. Before sectioning, each specimen was examined with hematoxylin and eosin staining by a pathologist to confirm tumor histopathology and to ensure that the specimen contained at least 70% tumor. Sectioned FFPE samples were deparaffinized with QIAGEN Deparaffinization Solution (QIAGEN, Germantown, Md), and total RNA was isolated with the QIAGEN miRNeasy FFPE kit and protocol. RNA samples were quantified with a NanoDrop spectrophotometer (NanoDrop Products, Wilmington, Del), and RNA integrity examined with the Agilent Bioanalyzer (Agilent, Santa Clara, Calif).
MATERIALS AND METHODS

Normalization and Quality Assessment
Total RNA was profiled with the Affymetrix GeneChip miRNA 3.0 array (Thermo Fisher Scientific, Waltham, Mass). Raw CEL files were normalized to produce probeset-level expression values and detection (Present/Absent) calls for all 5639 human and control probesets (including 1733 mature human miRNAs) with Affymetrix Expression Console (version 1.3.0.187), with the Robust Multiarray Average and Detection Above BackGround. Expression Console also was used to generate relative log expression (RLE) values as a measure of sample quality: a distribution of RLE values skewed upwards often indicates that the expression values were inflated by the normalization process. Samples with a mean RLE !0.5 or in which 20% of all miRNAs were called Present were excluded from analysis. Any miRNAs with spurious expression, ie, those that were not called Present in at least 25% of all samples, also were excluded from analysis.
The Cancer Genome Atlas (TCGA) Data
Preprocessed miRNA profiling data for primary tumors from 478 LSCC and 523 HNSCC TCGA samples, profiled by using Illumina Genome Analyzer (Illumina Inc, San Diego, Calif) or HiSeq instruments, were obtained from the National Cancer Institute's Genomic Data Commons (GDC) Portal at https://gdc-portal.nci.nih.gov. The data matrices used comprised counts that had been generated for 1881 human miRNAs in each sample via the use of miRBase version 21 
Statistical Analysis
Differential expression was assessed by performing a Student t test on the coefficients of simple linear models created with the ''limma'' R package (version 3.14.4). Correction for multiple hypothesis testing was performed with the Benjamini-Hochberg false discovery rate (FDR). Hierarchical clustering was performed with complete linkage and Euclidean distance metric, using expression values z-normalized to a mean of zero and standard deviation of one across all samples. All microarray analyses were performed using the R environment for statistical computing (version 2.15.1; the R Foundation for Statistical Computing, Vienna, Austria).
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
Complementary DNA (cDNA) was made with the TaqMan Advanced miRNA cDNA Synthesis kit and protocol. Quantitative real-time qPCR (qPCR) was performed with TaqMan Advanced miRNA Assays (Thermo Fisher Scientific) and Fast Advanced Master Mix (Thermo Fisher Scientific) using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, Calif). Three replicates of cDNA were made for each sample and duplicate qPCRs were set up for each cDNA. Within each PCR plate, pooled RNA from 8 samples (4 LSCC, 4 HNSCC) was included as a reference (calibrator), along with negative controls in which reverse transcriptase or template were excluded. TaqMan Advanced miRNA Assays were used to measure hsa-miR-191-5p (#477952_mir) and hsa-miR-361-5p (#478056_mir) as endogenous controls based on the array data. Relative expression of miR-34a was determined as normalized relative quantity using the method of Hellemans and colleagues, 9 that is, fold expression of miR-34a relative to the reference sample divided by the geometric mean of the fold expression of each endogenous control relative to the reference sample. The miR-10a:miR10b ratio was computed by raising 2 to the power of the difference between the DCt values for miR-10a and miR-10b (computed relative to the reference sample).
Spike-in controls were performed to establish primer specificity between miR-10a and miR-10b because of their sequence similarity. Yeast total RNA (Ambion; Thermo Fisher Scientific) was used as background and miR-10a and miR-10b RNA oligonucleotides (Integrated DNA Technologies, Coralville, Iowa) were used for the spike-in. Three replicates of cDNA were done for each sample, and 3 replicates of each cDNA were used for the PCR. Reactions in which reverse transcriptase or spike-in RNAs were excluded were used as negative controls.
RESULTS
Demographic and histopathologic information pertaining to the samples from our cohort and from primary tumors profiled by TCGA are summarized in Table 1 . In our cohort, the median time from resection to RNA isolation did not differ across tumor types: 29 months (interquartile range 10.8-39 months) for the LSCC samples, and 20 months (interquartile range 14.2-27.8 months) for the HNSCC samples (P ¼ .46, Student t test).
A total of 48 miRNAs were detected in at least 25% of all samples (see Materials and Methods) and had nominally significant differential expression between HNSCC and LSCC (P < .05), with 4 (miR-206, miR-10a, miR-4440, and miR-4793) passing multiple hypothesis correction (FDR q < 0.25) ( Figure 1 , Table 2 , and Online Data Supplement 1). Of the 25 miRNAs with significantly greater expression in LSCC, the difference was the most significant in the highly conserved miR-10a (P ¼ 4.5 3 10 À5 , FDR q ¼ 0.039), and intriguingly, the expression of the closely related miRNA miR-10b (which differs from miR-10a by only one nucleotide but shares its seed sequence) trended strongly in the opposite direction (1.7-fold greater in HNSCC, P ¼ .08). Another highly conserved miRNA, miR-34a, also was expressed at significantly greater levels in LSCC (P ¼ .004). Of the 48 miRNAs, 30 also were significantly (FDR q < 0.25) associated with tumor type in the same direction in both TCGA datasets (Table 2 and Online Data Supplements 2 and 3). Intriguingly, miR-10a was the most significantly differentially expressed miRNA whose expression was greater in LSCC in both TCGA datasets, indicating that this locus is very robustly associated with tumor type, and the expression of miR-10b also was associated strongly with tumor type in both TCGA datasets. Finally, miR-34a also was concordant in the TCGA datasets, ranking among the top 12% most significantly upregulated miRNAs in LSCC.
To assess possible sources of heterogeneity within HNSCC tumors, the TCGA datasets were used to perform a one-way analysis of variance with respect to anatomic site and to perform Student t tests between stage IV and nonÀstage-IV disease (Online Data Supplements 2 and 3). The expression of miR-10a was associated strongly with anatomic site (FDR q<0.25) in both datasets, whereas this held true for miR-34a in only the HiSeq dataset. The expression of miR-10b was not associated with site in either dataset (FDR q > 0.25). None of these 3 miRNAs was associated with stage IV disease in HNSCC in either dataset (all FDR q > 0.25).
Predictive Power of miR-10a:miR-10b Ratio
Given that the 2 highly related miRNAs miR-10a and miR-10b were strongly differentially expressed in opposing directions between LSCC and HNSCC in all 3 datasets, the Thoracic: Lung Cancer: Basic Science power of the miR-10a:miR-10b ratio as a discriminator between the two tumor types was examined ( Table 3 ). The performance of this ratio was examined with respect to (1) the platform used, (2) exclusion criteria (previous or unknown history of malignancy, chemotherapy or [in our cohort] radiation therapy; see Materials and Methods), However, consideration of HPV status produced mixed results, leading to little impact in the TCGA datasets, but a substantial improvement in the AUC in the microarray dataset (from 0.92 to 0.97).
Quantitative Real-Time PCR We then used qPCR to measure the expression of miR-34a, miR-10a, and miR-10b in our set of 28 samples. The normalized expression of miR-34a agreed well with the relative expression of miR-34a (normalized to the same controls) as measured by microarray (Figure 2 ; Pearson r ¼ 0.65), and, accordingly, the expression was significantly different between LSCC and HNSCC (Student P ¼ .049). The miR-10a:miR-10b ratio also was in good agreement with that determined by microarray (Figure 3 ; Pearson r ¼ 0.81). Interestingly, however, the magnitude and direction of the miR-10a:miR-10b ratio were rather 
DISCUSSION
Distinguishing between a primary LSCC and a metastatic lesion in a patient with a history of HNSCC is essential for determining cancer stage, prognosis, and therapeutic approach. However, this differentiation is difficult even after histopathologic assessment, the gold standard for the diagnosis of cancer. Patients with a history of HNSCC and the presence of lung metastases are considered to have advanced-stage cancers, and treatment will usually be aimed at palliation. 10 In contrast, if the same patient is diagnosed with a primary LSCC, this would be considered an early-stage lung cancer, which will have a better prognosis, with treatment focused on surgical resection with curative intent. 11 This differentiation also will help determine the appropriate surgical extent: for cases with lung metastases from HNSCC, a tissue-sparing, nonanatomical resection is indicated, such as metastasectomy or wedge resection, whereas the standard of care for a primary, early-stage lung cancer is a more extended or anatomical resection such as segmentectomy, lobectomy, or pneumonectomy, which have better survival rates but still possess considerable risk for complications. 4 Despite some limitations in the published literature, metastasectomy has shown to be beneficial in selected cases, with better survival rates compared with cases managed without surgery. 10, [12] [13] [14] These favorable results highlight the importance of having an accurate diagnosis that will help surgeons in the selection of the appropriate surgical approach and surgical resection extent. 
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The leftmost part of this table lists the 48 microarray probes described in Figure 1 , along with the 60 distinct miRNA transcript(s) that they interrogate, the coordinates of each transcript's alignment to the hg19 human genome build, the percentage of samples in which each probeset was called Present, signed linear fold changes computed between primary HNSCC and primary lung squamous cell carcinoma (eg, þ2 ¼ 2-fold higher in HNSCC, and À2 ¼ 2-fold lower in HNSCC), and the results of the Student 2-sample t test performed for each probeset between HNSCC and LSCC. The rightmost part of the table lists the corresponding transcript IDs from miRBase v21, along with signed linear fold changes and results of the Student 2-sample t test performed for each probeset between HNSCC and LSCC. Rows are sorted in descending order by the t statistic computed from the microarray data. Significant P values (P<.05) or FDR q values (FDR q<0.25) are indicated in bold. miRNA, MicroRNA; GA, Genome Analyzer; FDR, false discovery rate.
At least some of the differential expression observed between tumor types appears to be attributable to contamination of the tumor samples with surrounding tissue. The set of miRNAs that are expressed more highly in HNSCC than in LSCC in our cohort includes 4 ''myo-miRs'' (miR-206, miR-133a, miR-133b, and miR-1) whose expression has been well-established as restricted to striated muscle, 15 as well as miR-486-3p (which also has been reported to be enriched in muscle 16 and is intronic to the ANK1 gene, an isoform of which is specific to striated muscle and interacts with the muscle proteins titin 17 and obscurin 18 and miR-31, a ''dystromir'' that is a marker of skeletal muscle regeneration after injury 19 ). In addition, 7 miRNAs that are expressed more highly in HNSCC (miR-379, miR-411, miR-299, miR-381, miR-134, miR-377*, and miR-409) are located within the DLK1-DIO3 cluster in chromosome 14, which recently has been shown to be regulated by the transcription factor myocyte enhancer factor 2, 20 which is essential for myocyte differentiation and skeletal muscle growth. 21 The expression of all of these miRNAs also was significantly greater in HNSCC in both TCGA datasets, with the exception of 2 DLK-DIO3 cluster members (miR-379 and miR-409). Taken together, the increased expression of these miRNAs in HNSCC samples therefore likely represents contamination with surrounding striated muscle, which is unlikely to be present in LSCC specimens. Conversely, the expression of miR-34b*, miR-34c-5p, and miR-449a/b/c, whose expression is largely restricted to multiciliated cells (MCCs) such as those in the bronchial epithelium, 22 was more than 2-fold greater in LSCC than in HNSCC in our cohort and significantly (FDR q < 0.25) greater in LSCC in both TCGA datasets. Importantly, however, although miR-34a shares a seed sequence with these MCC-specific miRNAs, its pattern of expression is not restricted to MCCs and is therefore unlikely to represent contamination from the airway epithelium.
Several miRNAs that were expressed more highly in HNSCC in our cohort appear to be unrelated to striated muscle contamination, however, including miR-203 (P ¼ .028), which typically is regarded as a keratinocyte-specific miRNA 23 but has been detected in several squamous epithelia, including the esophagus, and is well-expressed in normal human bronchial epithelial cells grown in culture. 24 Another such miRNA is miR-455-3p (P ¼ .017), whose expression has been reported recently to be associated with increased survival in both HNSCC 25 and NSCLC. 26 The expression of both miRNAs also was robustly greater in HNSCC in both TCGA datasets (FDR q < 0.005).
Previous studies have shown that profiling of the expression of messenger RNA (mRNA) may be useful to discriminate between primary and metastatic lung squamous cell carcinomas in patients with a history of HNSCC. Talbot and colleagues 27 showed that an expression The performance characteristics (AUC, accuracy, sensitivity, specificity, PPV, and NPV) are summarized according to platform, exclusion criteria, HPV status, and exclusion or inclusion of non-stage-IV HNSCC. HPV, Human papillomavirus; HNSCC, head and neck squamous cell carcinoma; AUC, area under the (receiver operating characteristics) curve; PPV, positive predictive value; NPV, negative predictive value.
profile of 100-500 genes could accomplish this goal. Similarly, Vachani and colleagues 28 produced a 10-gene classifier that distinguished between primary lung and metastatic lesions, but the results of that study appear to be confounded with differences in cell type composition, as the classifier includes the lung surfactant SFTPB (whose expression is greater in LSCC) and the striated muscle markers TMP3 and MYH2 (whose expression is greater in HNSCC), and the larger set of discriminators included the lung surfactant genes (SFTPC, SFTPD), airway secretory epithelial markers (SCGB1A1 and MUC5B), and an alveolar marker (ABCA3), as well as the striated muscle markers ACTA1, ANK3, MYL1, and TPM2. The authors discuss the possibility that the increased expression of the lung surfactant genes in LSCC may be attributable to contamination with nontumor lung tissue, and indicated that SFTPC in particular may be expressed by LSCC; however, they did not address the presence of the muscle-specific markers in their predictive gene sets.
The use of miRNA profiling to establish discriminators between these 2 tumor types could be a more useful and accurate technique than mRNA expression profiling, as miRNAs are more resistant to degradation and remain largely intact in FFPE samples for longer time than mRNA, and are also recognized for their tissue specificity. This possibility was explored by Rosenfeld and colleagues, 29 who used miRNA expression in tumor samples to derive a decision tree to infer the primary tissue of origin. Importantly, miR-34a was 1 of only 3 miRNAs (along with miR-148b and miR-182) that were used to discriminate between LSCC and HNSCC in this tree (all 3 expressed more highly in LSCC). Although the latter 2 miRNAs were not significantly differentially expressed in our cohort, their expression was significantly greater in LSCC in both TCGA data sets (FDR q < 10 À7 ). This discrepancy may be explained by the difference in sample size, but as miR-148b and miR-182 also are expressed at relatively low and high levels, respectively, the improved FIGURE 2. Relative expression of miR-34a. Expression of miR-34a was measured in each lung squamous cell carcinoma (light green) or head and neck squamous cell carcinoma (dark green) sample by microarray (hatched bars) and quantitative real-time polymerase chain reaction (solid bars). Microarray expression was exponentiated to convert to linear scale, and then relative expression was computed as the ratio of miR-34a to the geometric mean of miR-191-5p and miR-361-5p. Similarly, qPCR relative expression was computed relative to an interplate reference sample and then separately to miR-191-5p and miR-361-5p to obtain 2 measurements for each replicate, which were averaged together using the geometric mean. Bars for qPCR measurements indicate mean AE SEM. qPCR, Quantitative real-time polymerase chain reaction. dynamic range and specificity of RNA sequencing also may contribute to this difference.
One of the most striking results of this study is the strong and robust association of the miR-10a:miR-10b ratio with tumor type, with the expression of the former and latter strongly increased in LSCC or HNSCC, respectively. This reciprocal relationship is not entirely surprising, as miR-10b is located $1 kb upstream of HOXD4, a known target of miR-10a. 30 The particular advantage of using a ratio of 2 miRNAs as a discriminator is that it removes the need to select and profile an appropriate a housekeeping control, as each miRNA serves as the internal control for the other. This approach also was explored by Vachani and colleagues, 28 but as all of their ratios included a lung surfactant gene (SFTPA2 or SFTPB), it is likely that their results reflect relative presence of contaminating normal lung tissue rather than biological differences between the 2 tumor types.
Although this study has demonstrated that the expression of a small number of miRNAs may be useful in clinical discrimination of primary LSCC and HNSCC tumors, several challenges remain. Contamination of tumor samples with surrounding tissue such as striated muscle or airway epithelium is a limitation that could be addressed in future studies with the use of laser capture microdissection to isolate tumor cells before profiling and increase statistical power to discriminate between tumor types, although this technique is too cumbersome to be useful in routine diagnostic practice. A more important future goal, however, is to obtain more samples, especially those from solitary lung lesions found in patients with a history of HNSCC (and, where possible, matched HNSCC samples from the same subject).
CONCLUSIONS
The distinction between a primary LSCC and a metastatic lesion in a patient with a history of HNSCC is difficult even after histopathologic assessment. The differentiation between these 2 is essential because this will determine the prognosis and the selection of the appropriate therapeutic approach. The expression of several miRNAs may be useful for discriminating between HNSCC and LSCC, including the expression of miR-34a and the ratio of the expression of miR-10a and miR-10b.
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Authors have nothing to disclose with regard to commercial support. comes in with a lung nodule and they previously had head and neck cancer, is this metastasis or is this primary? Do miRNAs change during metastasis? If you looked at actual lung lesions from head and neck metastases, would you see the same results?
Dr Munoz. We actually tried to look at the samples from the primary and from the metastatic lesions. We are looking for these patients. We don't know at this moment if the expression is the same, but we know that miR-10b is related with invasiveness in breast cancer, as reported in the literature. So we could say that maybe the expression of miR-10b is greater in the metastatic lesion. But, yes, that would be very interesting to see, and we are trying to actually find these cases with the primary lesion and the metastatic lesion to compare the miRNA signature.
Dr Onaitis. Nice job. Dr Shaf Keshavjee (Toronto, Ontario, Canada). I have another question that is more philosophical: if you look at a single biomarker, you have to examine expression in the 2 tumors and then find a cutoff level. You know that most of our biomarkers to date, depending on how good they are, may be expressed to a certain degree in certain parts of tumors, but not 100%. If you really wanted to specifically answer the question of: Is this tumor in the lung a metastasis from the head and neck or a new primary, wouldn't we be better looking at overall array patterns of expression to really answer that question and then go to personalizing your therapy based on what the current tumor is that you are treating? Array patterns that are so dramatically different would tell you that it is a different tumor rather than expression level comparison of one marker.
Dr Munoz. I'm not sure if I completely understand the idea. The interesting thing here is that we can see what the expression in these 2 different tumors is, but I am not sure.
Dr Keshavjee. What my question related to is, when you showed the microarrays, the first question that came into my head is what does the array of the same tumor from the head and neck and from the lung in that patient look like and how many genes were co-upregulated or down-regulated in the same tumor side by side? That would be the comparison that would be very interesting to see.
Dr Virginia Litle (Boston, Mass). I agree. When you are talking about using a biomarker to guide clinical decision-making, you really do have to have as high an accuracy rate as possible, and ours is pretty high, but I think we are also trying to work toward developing something that would be practical, and the idea is that you could do a CT-guided or a navigational bronchoscopic biopsy of the lesion, and then you could do PCR. It may end up being a panel of biomarkers, but if we can narrow it down to a few in number, we could actually use it clinically versus having a lower throughput test, like arrays.
Dr Keshavjee. Great. Good point.
